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Induction of insulin resistance in normal adipose tissue
by uremic human serum
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Induction of insulin resistance in normal adipose tissue by uremic
human serum. An incubation of uremic human serum with normal rat
adipose tissue will make the subsequently isolated adipocytes less
responsive to insulin. To examine the extent of insulin resistance, we
obtained sera from nondiabetic, uremic patients, who had not under-
gone dialysis therapy. The sera were then dialyzed (3500 molecular-
weight cutoff) for 18 hr against a defined culture medium to eliminate
possible in vitro effects of altered levels of end-product metabolites,
electrolytes, and metabolic substrates. After an incubation of epididy-
mal fat tissue from normal rats, for 3 hr with the dialyzed sera (50%
vollvol), cells were isolated and washed. The insulin stimulation of '4C-
glucose (0.2 mM) incorporation to '4C02 and total lipids was significant-
ly reduced in the adipocytes pretreated with sera from 19 of the 29
uremic patients. Although elevated in the uremic patients, the sera
levels of insulin, and parathyroid and growth hormones were not
correlated to insulin resistant activity. Furthermore, incubation of
adipose tissue for 3 hr with insulin, glucagon, or PTH did not produce
resistance. The uremic sera reduced glucose utilization equally at 0.2
and 50 m glucose, suggesting that the insulin resistance was induced
additionally at a site distal to the glucose transport system. However,
the concentration of insulin (22 U/ml) required for half-maximal
stimulation of glucose metabolism was not altered by pretreatment with
uremic serum. Also, neither the isoproterenol-stiniulated lipolysis nor
the inhibition of this cellular event was influenced by pretreatment
with uremic sera. Thus, the serum factor(s), which is not an end-
product metabolite or a known glucoregulatory hormone, produces an
insulin-resistant state similar in several aspects to that of tissue from
uremic animals.
Induction d'une résistance a l'insuline dans du tissu adipeux normal
par du serum humain urémique. L'incubation de serum humain uré-
mique avec du tissu adipeux de rat normal rendra les adipocytes isolés
ensuite moms sensibles a l'insuline. Afin d'examiner l'importance de Ia
résistance a l'insuline, nous avons obtenu des serums de malades
urCmiques, non diabétiques, n'ayantjamais éte en dialyse. Les serums
ont ensuite été dialyses (limite de poids moléculaire 3500) pendant 18 hr
contre un milieu de culture défini pour éliminer les effets in vitro
possibles des niveaux altérés des métabolites terminaux, de électro-
lytes, et des substrats metaboliques. Après incubation de tissu grais-
seux épididymaire de rats normaux pendant 3 hr avec les serums
dialyses (50% vol/vol), les cellules étaient isolées et lavees. La stimula-
tion par l'insuline de l'incorporation de '4C-glucose (0,2 mM) en
et les lipides totaux étaient significativement réduits dans les adipocytes
pré-traités avec les serums de 19 des 29 malades urémiques. Bien
qu'élevés chez les urémiques, les niveaux sériques d'insuline, et
d'hormone parathyroidienne et de croissance n'étaient pas corrélés a
résistance a l'insuline. En outre, l'incubation de tissu adipeux pendant 3
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hr avec de l'insuline, du glucagon ou de l'hormone parathyroIdienne n'a
pas entrainé de résistance. Les serums uremiques ont réduit l'utilisation
de glucose de facon egale pour 0,2 et 50mM de glucose, suggerant que la
résistance a l'insuline était induite additionnellement a un site plus
distal que le système de transport du glucose. Cependant, Ia concentra-
tion d'insuline (22 jUIm1) nécessaire ala stimulation demi-maximale du
métabolisme du glucose n'était pas altérée par le prd-traitement avec du
serum urémique. Egalement, ni Ia lipolyse stimulée par l'isoprotérénol,
ni l'inhibition de ce phdnoméne cellulaire n'était influencées par le pré-
traitement avec les serums uremiques. Ainsi, ce(s) facteur(s) serique(s),
qui n'est pas un métabolite terminal ni une hormone glycorégulatrice
connue, produit un ètat de résistance a l'insuline, identique par plu-
sierus aspects a celni des tissus d'animaux uremiques.
The presence of insulin resistance in many patients with
chronic renal failure has been well documented [1]. It is clear
that several target tissues for insulin are less responsive to this
glucoregulatory hormone. The insulin stimulation of glucose
uptake by skeletal muscle, measured by the forearm perfusion
technique, is reduced in uremic patients [2]. In addition, insulin
action can be studied by the euglycemic insulin clamp. In these
experiments, blood insulin is kept at a constant, elevated
concentration, while simultaneously maintaining stable levels
of glucose (—90 to 100 mg/dl) by continual infusion. The amount
of glucose that has to be infused to maintain euglycemic levels
reflects the quantity of glucose taken up by peripheral tissues in
response to insulin; this is reduced in uremia [31. We have
recently found the epididymal adipose tissue of urernic rats to
be less responsive to the stimulatory actions of insulin in the
absence of any alteration in insulin binding [4].
In an early examination of the glucose intolerance of nondia-
lyzed, uremic patients, Hampers et al reported a significant
improvement of glucose utilization after the patients had under-
gone dialysis therapy for longer than 2 weeks [51. This has been
substantiated by the experiments of DeFronzo et al using
insulin clamp techniques to determine insulin-responsiveness of
target tissues [3]. From these observations, it was suggested
that a substance(s) in the blood of uremic patients may be
responsible for inducing insulin resistance [5]. Furthermore, the
incubation of whole [6, 7] or partially purified [81 sera, obtained
from chronic uremic patients, reduced the basal uptake of
glucose by a variety of normal tissues. Recently, the insulin
stimulation of glucose uptake into adipocytes was shown to be
inhibited by preincubation of the tissue with uremic serum [41.
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In the present study, we have investigated the effect of uremic
serum on metabolic actions of insulin, other than glucose
transport, to characterize the extent of the induced insulin
resistance. In addition, initial studies were done to further
define a resistance factor by excluding multiple hormones and
end-product metabolites as possible candidates.
Methods
Materials. Male Sprague-Dawley rats were obtained from
Charles River Laboratories, Wilmington, Massachusetts. Crys-
talline porcine insulin was a gift of the Eli Lilly Company,
Indianapolis, Indiana. Worthington Biochemical Corp., Free-
hold, New Jersey, supplied crude collagenase (type 1), and
bovine albumin fraction V (BSA) was obtained from Reheis,
Kankakee, Illinois. All radioisotopes were obtained from Amer-
sham Corp., Arlington Heights, Illinois. SpectraiPor 6, dialysis
tubing with a molecular weight cutoff of 3,500,was supplied by
Arthur Thomas Co., Philadelphia, Pennsylvania. The synthetic
N-terminal fragment [1—34] of bovine PTH (6800 lU/mg) was
obtained from Beckman, Palo Alto, California. Glucagon was
supplied by Sigma Chemical Co., St. Louis, Missouri.
Patient characteristics. Samples of serum were obtained
from 17 male and 12 female patients, who ranged in age from 21
to 88 years. Blood was drawn at various times of the day,
however, usually in the postabsorptive state. These patients
were diagnosed as having uremia according to established
criteria [9]. Their ranges of urea nitrogen and creatinine levels
were 45 to 200 (X SD, 109 42) and 3.6 to 15 (7.3 3.2)
mg/dl, respectively. Further characteristics of the patients are
presented in Results. These patients were not receiving gluco-
corticoid treatment or any other drugs known to alter glucose
tolerance. None of them had received either dialysis therapy or
had any evidence of diabetes mellitus according to established
criteria [10] (for example, overnight fasting blood glucose levels
were less than 140 mg/dl). All patients were informed of the
study and consent was obtained. The pooled control serum was
obtained from 20 subjects, ranging in age from 20 to 70 years,
who were known to be free of renal disease and other insulin-
resistant states, such as obesity or diabetes mellitus.
Adipose tissue culture and cell isolation. Sera were dialyzed
18 hr (4°C) against Parker's Medium 199 (100-fold excess
volume) using cellulose dialysis tubing. Epididymal adipose
tissue derived from male rats (180 to 230 g) was pooled, minced,
and preincubated for 3 hr with human serum (50% vol/vol),
from either normal subjects (control) or uremic patients, and
Medium 199, which contained I g/dl BSA and 0.3 mg Hepes/ml,
at pH 7.4, using a humidified atmosphere of 95% 02/5% CO2 at
37°C [4]. The adipocytes were then isolated by collagenase
digestion [11] in Krebs-Ringer phosphate buffer, pH 7.4, that
contained 3 g/dl BSA. The cell suspensions were maintained in
this buffer after the removal of collagenase by three washings.
As noted previously [4], substitution of the Medium 199 con-
taining BSA with dialyzed serum from control subjects did not
influence the subsequent action of insulin on adipocytes. The
cytosolic space [12] of control and uremic-sera pretreated cells
(0.08 0.02 and 0.08 0.02 td/l05 cells, X SEM, respectively)
were not significantly different than that of cells preincubated
with the defined culture medium (0.07 0.01 ,tdIlO5 cells).
Glucose metabolism. Adipocytes, which had been pretreated
with either control or uremic sera, were incubated at 37°C with
Table 1. Effect of dialysis on some constituents of seruma
Serum constituents
Serum source
Control Uremic
Creatinine, mg/d/
Urea nitrogen, mgldl
Glucose, mgldl
K, mEqiliter
Na, mEqidi
Cl, mEqidi
Ca, mgldl
Mg, mEqIdl
P04, mgldl
pH
0
<1
93
5.7
155
132
9.0
1.9
2.4
7.4
0
<1
93
5.7
154
132
8.6
1.9
2.0
7.4
a Sera were dialyzed 18 hr (4°C) against Medium 199 using dialysis
tubing of 3,500 molecular weight cut-off.
either 0.2 or 50 mrvi D-U-(14C)-glucose (sp act 0.67 or 0.023
Cilmmoles, respectively) and in the absence or presence of
insulin (1000 U/ml) as described previously [4]. After 90 mm,
oxidation of glucose was determined by trapping '4C02 with
ethanolamine:3-methoxyethanol: :1:2 (vollvol) in a hanging
well, and incorporation of glucose into total ('4C)-lipid by
extracting with Soluscint 0 (National Diagnostics, Somerville,
New Jersey) liquid scintillation fluor and then counting the
organic phase [13]. Because of the usual between-day variation
in the quantity of glucose utilization, the metabolism by cells
pretreated with uremic serum was compared to that by cells
pretreated with normal serum, always within each experiment.
The percent of inhibition by a serum sample was significantly
correlated (r = 0.95, P < 0.001) with the percent of inhibition on
repeated experiments.
Lipolysis assay. Adipocytes, which had been pretreated with
either control or uremic sera, were incubated in Krebs-Ringer
phosphate buffer, pH 7.4, containing 0.5 m glucose and 3 gJdl
BSA, with or without i07 M DL-isoproterenol-HC1 at 37°C for
60 mm. In addition, various concentrations (0 to 1000 U/ml) of
insulin were present. The assay was terminated by the addition
of 5 g/dl trichloroacetic acid and centrifugation at x 10,000g (2
mm). The amount of lipolysis was determined by measuring the
quantity of glycerol within the supernatant after removal of the
fat cake [14].
Serum measurements. Urea nitrogen was determined by
diacetyl monoxime colorimetric assay and creatinine by the
picric acid reaction assay, both from Sigma Chemical Co., St.
Louis, Missouri. All hormones were measured in one run.
Growth hormone levels were measured by radioimmunoassay
with an intra-assay variation of 10% as described [15]. A
radioimmunoassay, which had an intra-assay variation of 6.8%
was used to measure cortisol (Clinical Assays, Cambridge,
Massachusetts). PTH was determined by radioimmunoassay to
the carboxy-terminal fragment according to Insogna et al [16]
with an intra-assay variation of 10.4%. The levels of all hor-
mones were determined on nondialyzed sera.
Results
The serum obtained from control and uremic humans was
subjected to 18 hr of dialysis against the same defined culture
medium that was used for fat tissue preincubations. As shown
in Table 1, the concentrations of ions, pH, metabolic sub-
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Fig. 1. Relationship of serum creatinine and
urea nitrogen to insulin-resistant activity.
Values are the quantity of either creatinine or
urea nitrogen in each serum sample before
dialysis and the percent inhibition of insulin-
stimulated (1000 UIml) glucose utilization
(0.2 mM) by that sample of dialyzed serum
from 29 individual uremic patients. The
shaded area accounts for 99% of the variation
(2.31 SD) by control sera. The range of
creatinine and urea nitrogen levels in the sera
from control subjects were 0.9 to 1.3 and 13 to
24 mgldl, respectively.
Fig. 2. Relationship of serum hormone levels
to insulin-resistant activity. Values are the
quantity of a hormone in each serum sample
before dialysis and the percent inhibition of
insulin-stimulated (1000 U/m1) glucose
utilization (0.2 ruM) by that sample of dialyzed
serum from individual uremic patients. The
shaded area accounts for 99% of the variation
(2.31 SD) by control sera. The range of insulin,
PTH, cortisol, and growth hormone levels in
the control subjects were 13 to 24 U/ml, 4 to
5 alEqIm1, 6 to 15 g/dl, and 0.9 to 5 ng/ml,
respectively.
strates, and end-product metabolites such as urea nitrogen and
creatinine, were equivalent in the control and uremic sera after
dialysis. The inhibition of insulin-stimulated glucose utilization
by urernic serum was not altered by the dialysis procedure [18
6% (X sE) or 19 6% inhibition with or without dialysis,
respectively].
The amount of insulin-resistance induced by the dialyzed
serum from each uremic patient was considered statistically
significant if the suppression of insulin-stimulated glucose utili-
zation (at glucose concentration of 0.2 mM) exceeded 2.31 SD of
the control value, that is, an inhibition >9%, which is equiva-
lent to P < 0.01. Based on this criterion, the sera from 19 of 29
(66%) uremic patients had significant amounts of insulin-resist-
ant activity. The inhibition produced by the sera from the group
of uremic patients, shown in Figure 1, ranged from 0 to 37%. As
seen in this figure, there appears to be a pronounced presence
or absence of insulin-resistant activity in the sera, independent
of our statistical criterion, suggesting two populations of uremic
patients. The relationship of the resistant activity in the dia-
lyzed uremic sera to the level of either creatinine or urea
nitrogen in the predialysis sera is also shown in Figure 1. There
was a significant correlation (r = 0.58, P < 0.01) between
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Preincubation
Final assay
Glucose metabolismb
nmoles/lO5cells/90 mmSerum additions
None 7.7 0.9w
Insulin, io to 107M 8.1 0.9
Glucagon, 105M 7.3 0.5
PTH, 1o8 — 104M 7.9 0.8
insulin resistance and urea nitrogen levels before dialysis. It
should be remembered, however, that urea nitrogen levels were
<1 mgldl for all sera during testing (Table 1) due to the 18 hr of
dialysis. There was inhibitory activity in the sera from 81% of
the patients that had urea nitrogen levels above 80 mgldl.
The mean (± SEM) values of all hormones measured in the
nondialyzed sera from the uremic patients (insulin, 32 4
LU/ml; cortisol, 20 3 g/dl; PTH, 236 70 pJEq/ml; growth
hormone, 3.6 0.5 nglml) were higher than in the nondialyzed
sera from control subjects (18 2 tU/ml, 11 3 /Lgldl, 5 0.3
dEq/ml and 2.3 1.3 nglml, respectively) (Fig. 2). There was a
significant (r = 0.68, P < 0.01) correlation between the concen-
trations of cortisol in the nondialyzed uremic sera and the
inhibition of insulin-stimulated glucose utilization by these sera.
No other hormone correlated with the resistant activity. The
levels of glucagon, in the sera used for preincubation, were not
above detectable levels because of its rapid degradation without
the addition of protease inhibitors [17]. To further test the
possibility that an elevated concentration of a known glucoregu-
latory hormone might be responsible for the insulin resistance,
we incubated adipose tissue with control serum that had added
to it either insulin, glucagon, or PTH. There was no significant
suppression of glucose utilization by any of these hormones
after a 3-hr preincubation (Table 2). Previously our laboratory
found a 2- to 4-hr incubation of fat tissue with either growth
hormone or glucocorticoids that did not inhibit the insulin
stimulation of glucose utilization [18, 19].
The decrease in basal glucose utilization (0.4 nmoles/105
cells/90 mm), at 0.2 m glucose, accounted for only part of the
2.2 nmoles inhibition in the presence of insulin. There were no
significant differences in the percentage decrease of CO2 (13
4%) versus lipid (14 4%) production. The reduction in glucose
metabolism, at the low glucose concentration of 0.2 m, used in
Figures 1 and 2, could be due entirely to the alteration of the
glucose transport system, which we demonstrated previously
[4]. To determine if an additional cellular lesion was induced by
the uremic sera, we examined the glucose utilization of pre-
treated adipocytes at a glucose concentration (50 mM) that was
not rate-limited by transport (Fig. 3). There was an equivalent
reduction of glucose utilization at the two glucose concentra-
tions, both in the absence and presence of insulin (1000 U/ml),
suggesting that both transport and metabolism were inhibited.
The uremic sera did not change the sensitivity nf i'vt.c
Fig. 3. Effect of uremic serum on glucose utilization by adipocytes.
Values are the percent inhibition of glucose metabolism, at either 0.2
(D) or 50(U) mriglucose, by uremic sera. The serum from each of three
uremic patients was examined on a separate day, but all experimental
conditions were run in parallel on the same day. The basal metabolism
of U-'4C-glucose into '4C02 and '4C-lipids by control cells were 3 or 39
nmoles/l05 cells/90 mm at 0.2 or 50 ms glucose, respectively. In the
presence of insulin (1000 U/ml), the control responses were either 11
or 59 nmolesll05 cells/90 mm at 0.2 or 50 m glucose, respectively.
to submaximally effective concentrations of insulin in the
presence of 0.2 mst U-'4C-glucose (Fig. 4). The insulin sensitiv-
ity was defined as the dose response for the hormone that exists
between no effect and the maximal response [201. The half-
maximal response for insulin-stimulation of glucose utilization
was equivalent (—22 iU/ml), although basal and maximal
stimulation were inhibited.
The lipolytic activity of cells, which were preincubated with
uremic sera, were not different from control, although the same
uremic sera inhibited glucose utilization. As shown in Figure 5,
the concentration of insulin, which was required to induce a
half-maximal inhibition of stimulated lipolysis, was —8 U/ml
for both sets of adipocytes. Basal release of glycerol was 0.31
0.05 and 0.29 0.07 g/i05 cells/60 mm (X SEM) for control
and uremic-sera pretreated cells, respectively. In the presence
of iO— M isoproterenol, glycerol release was increased to 1.75
0.13 and 1.64 0.20, respectively. At the concentration of
insulin (50 MU/mI) that produced a maximal inhibition of
isoproterenol-stimulated lipolysis, again the release of glycerol
was not different (0.6 0.1 and 0.5 0.1 jg/i05 cells/60 mm for
control and uremic pretreatment, respectively). The same re-
sults were obtained by using uremic sera that did not signifi-
cantly inhibit glucose utilization.
Discussion
The insulin resistance that frequently accompanies chronic
renal failure has been suggested to be due to a circulating
factor(s) for several reasons. First, abnormal responses to
either a glucose tolerance test [5] or an euglycemic insulin
clamp [31 are significantly improved with hemodialysis therapy.
Second, the epididymal fat pads from uremic rats can recover
from an insulin-resistant state when cultured for 20 hr in a
defined medium [4]. Third, sera from uremic patients inhibit
basal utilization of glucose by muscle and erythrocytes [6—8).
Finally, the insulin-stimulation of glucose transport into adipo-
cytes is reduced significantly when the fat tissue is preincubated
u,fI, —,-s--. 1A1
Table 2. Effect of preincubation with peptide hormones on insulin-
stimulated glucose metabolism
Insulin
Basal (1000 aLJ/mI)
C0
cnC =
—Q0
a Hormones were added to control serum (50% concentration with
Medium 199) during the 3-hr preincubation.
b Glucose metabolism is represented by '4C—glucose (0.2 mM) incor-
poration into '4C02 and '4C-total lipids in the presence of insulin (1000
U/ml). -
Values are X SE of six experiments.
—10
—20
420 McCaleb et at
Insulin, p.1.1/mi
Fig. 5. Effect of uremic serum on antilipolysis by insulin. Isoproterenol
(10 M) stimulation of lipolysis by adipocytes, pretreated wth control(•) or uremic (0) sera, was inhibited by various concentrations of
insulin. The values, mean of four experiments, represent a percentage
of the maximal insulin-induced inhibition of isoproterenol-stimulated
lipolysis.
Kahn [20], is also consistent with the postreceptor defect. In
other studies of insulin-resistance, such as obesity and/or
diabetes mellitus, there is also a decrease of insulin-stimulated
glucose utilization by adipocytes without a substantial change
in the antilipolytic action of insulin [221.
As noted in Figures 1 and 2, not all of the sera, obtained from
patients with chronic renal failure, are able to induce insulin
resistance. This result is consistent with the findings of previous
reports [1] in which only a portion of the uremic population
studied had evidence of insulin resistance. However, the degree
of uremia appears to play some role in the presence of insulin
resistance since there is a correlation between the serum levels
of urea nitrogen and the insulin resistant activity of the uremic
serum.
In our earlier report [4] sera were obtained from a few uremic
patients under more uniform conditions. However, the necessi-
ty to examine the serum from a larger and more diverse
population of uremic patients within this study, precludes a
comprehensive evaluation of the insulin-resistant state of each
patient based on their substrate and hormone levels in the
postabsorptive condition. In addition, the patients utilized in
this study had diverse serum electrolytes, acid-base balance,
severity of chronic renal failure, and a moderate range of body
weights.
The serum concentration of many hormones are substantially
increased during the chronic renal failure. Furthermore, the
elevation of hormones, such as insulin, glucagon, growth hor-
mone, PTH, or cortisol, during other disease states has been
associated in many instances with insulin resistance [23—27].
However, the results of our study and other investigators [28]
suggest that these hormones do not appear to be directly or
uniformly responsible for inducing the insulin-resistant state in
uremia. There is no evidence of insulin resistance after preincu-
bating fat tissue for 2 to 4 hr with any of these hormones (Table
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Fig. 4. Effect of uremic serum on insulin sensitivity. Insulin stimulation
of glucose utilization (CO2 + lipid) by adipocytes pretreated with either
control (•) or uremic (0) sera is expressed as a percentage of the
maximum quantity stimulated above basal levels in three experiments.
Basal metabolism was either 3.39 or 3.13 nmoles/105 cells/90 mm for
control or uremic-sera pretreated cells, respectively, and the maximal
insulin-stimulated response was 14.78 or 11.97 nmoles/105 cells/90 mm,
respectively.
Although the transport of glucose by an insulin-sensitive
tissue from uremic rats is clearly altered [4], it is possible that
there are other cellular lesions. The reduction in glucose
metabolism, at the low glucose concentration of 0.2 m, could
be due entirely to alterations of the glucose transport system.
However, had the lesion been restricted to glucose transport,
there would be minimal inhibition at the high glucose concentra-
tion of 50 mivi [191. Since there is a significant reduction of
glucose utilization at 50 mM, it is probable that the insulin
resistance is induced additionally at a site distal to the transport
of glucose. Interestingly, lipogenesis and carbon dioxide pro-
duction were inhibited equally. Furthermore, the inhibition of
glucose metabolism, in the presence of insulin, cannot be
accounted for quantitatively by a reduction of basal metabolism
alone. There is an additional lesion in the response of adipo-
cytes to insulin.
Not all aspects of insulin's actions are affected by the uremic
factors. The antilipolytic effect of insulin is not different after
preincubation of tissue with uremic serum. Therefore, insulin's
ability to stimulate anabolic events is reduced without altering
its simultaneous inhibition of lipid mobilization. This observa-
tion is further evidence that the primary lesion is not at the level
of insulin receptor as we [4] and other investigators [21] have
reported, because if it had been, both biologic actions of insulin
would be retarded. The lack of a change in the sensitivity of the
cells to various concentrations of insulin (Fig. 4), as defined by
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2)118, 19]. With the exception of cortisol, there is no correlation
between the quantity of any of the hormones and the amount of
inhibitory activity we measured. Although there is a significant
correlation between cortisol levels in uremic patients and
insulin resistance, elevated levels of this hormone in sera do not
always induce insulin resistance. However, the possibility that
chronic hypercorticism can induce a serum factor similar to that
seen in uremia warrants further investigation.
Our studies continue to provide evidence that a circulating
factor(s) is responsible for producing the insulin resistance in
uremia. The defects in tissue from uremic rats are recreated
with the same characteristics by preincubating normal tissue
with uremic serum. In both conditions, the insulin resistance
could be ascribed to alterations in glucose transport and metab-
olism without any change in the insulin receptor. Our labora-
tory is presently attempting to purify and characterize further
the uremic factor(s) that induces insulin resistance.
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